Company intelligence / Profile preview

RS BioTherapeutics

Cumberland, Maryland, United States

Ownership: Private
Employees: ~3
Development stage: Other

Overview

RSBT-001, their lead compound, has shown statistically significant anti-inflammatory and anti-fibrotic effects in animal studies and human lung tissue models, with significant reductions in key inflammatory and fibrotic biomarkers relevant to COPD and IPF. First-in-human trials are planned post-IND submission in 2026.[1][2][5]

Therapeutic areas: CardiovascularPulmonologyInfectious Diseases
Modalities: Small moleculeSemi-synthetic cannabidiolic acid complexBiologic
Industry: Biotech

Partnerships

University of Colorado School of Medicine (academic collaboration)FibroFind (preclinical services company for tissue modeling)[1]

Beyond the preview

Go deeper on RS BioTherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RS BioTherapeutics.

Explore the full profile